Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 407 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Food for thought: new insights into how chemotherapy causes cachexia June 15, 2022 Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... January 29, 2024 Inside Cancer Grand Challenges Part 1: what makes a grand challenge? June 16, 2022 EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... June 24, 2022 Load more HOT NEWS Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate... Grace and Love for Full Hands EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical...
